Kala Bio (KALA) Long-Term Debt Issuances (2018)

Kala Bio (KALA) posted Long-Term Debt Issuances of $69.2 million for Q4 2018, up 2436.62% sequentially from $2.7 million in Q1 2018.

Kala Bio (KALA) Long-Term Debt Issuances (2018) Analysis & Trends

Kala Bio has reported Long-Term Debt Issuances for 1 years, with the latest figure at $69.2 million in Q4 2018.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $69.2 million in Q4 2018, while the trailing twelve-month figure through Dec 2021 was $69.2 million (changed N/A YoY) and the FY2021 annual result came in at $77.8 million, changed N/A from the prior year.
Long-Term Debt Issuances grew to $69.2 million in Q4 2018 per KALA's latest filing, from $2.7 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $69.2 million in Q4 2018 and troughed at $2.7 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Kala Bio	9.89 Mn	9.89 Mn	-	-

Download Data